Commentary
Video
Dr Kalinsky on Abemaciclib/Fulvestrant in HR+/HER2– Breast Cancer Post–CDK4/6i Progression
Author(s):
Kevin Kalinsky, MD, MS, on abemaciclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a CDK4/6 inhibitor and endocrine therapy.
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University, discusses results from the phase 3 postMONARCH trial (NCT05169567) evaluating abemaciclib (Verzenio) plus fulvestrant (Faslodex) vs fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer who had disease progression on a CDK4/6 inhibitor and endocrine therapy.
